AbbVie to buy venture-backed Stemcentrx in deal that could reach $10 bln
AbbVie Inc agreed to acquire venture-backed Stemcentrx in a deal valued at about $5.8 billion, which includes $2 billion in cash and the remainder in stock. Backers include Fidelity Investments. The company, which was backed by Artis Ventures and Founders Fund.
28 April 2016•1 min read
